Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
NGM Biopharmaceuticals (United States)
InstitutionResearch output, impact & collaborations
NGM Biopharmaceuticals (United States) is a research organisation in South San Francisco, US. OpenAlex records 616 works and 121,297 citations for it. 211 researchers list it as their most recent affiliation.
616
Works
121,297
Citations
211
Researchers
55.5
Avg h-index
How has NGM Biopharmaceuticals (United States)'s publication output changed over time?
ScholarIQpublication output · 2003–2024
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2024.
1
2
3
2
2
1
1
2003201320142016201720182024
Who are the most-cited researchers behind NGM Biopharmaceuticals (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on NGM Biopharmaceuticals (United States)?
ScholarIQmost cited works
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
Nature Medicine. 20181,263 CitationsOPEN ACCESS
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
Joshua B. Rubin, Andrew L. Kung, Robyn S. Klein, Jennifer A. Chan, Yanping Sun, Karl Schmidt, Mark W. Kieran, Andrew D. Luster, Rosalind A. Segal
Proceedings of the National Academy of Sciences. 2003612 CitationsOPEN ACCESS
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Priscilla K. Brastianos, Amaro Taylor‐Weiner, Peter Manley, Robert T. Jones, Dora Dias‐Santagata, Aaron R. Thorner, Michael S. Lawrence, Fausto J. Rodríguez, Lindsay A. Bernardo, Laura Schubert, Ashwini Sunkavalli, Nick Shillingford, Monica L. Calicchio, Hart G.W. Lidov, Hala Taha, Maria Martinez‐Lage, Mariarita Santi, Phillip B. Storm, John Y. K. Lee, James N. Palmer, Nithin D. Adappa, R. Michael Scott, Ian F. Dunn, Edward R. Laws, Chip Stewart, Keith L. Ligon, Mai P. Hoang, Paul Van Hummelen, William C. Hahn, David N. Louis, Adam Resnick, Mark W. Kieran, Gad Getz, Sandro Santagata
S137905309. 2014518 CitationsOPEN ACCESS
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma
Adam M. Fontebasso, Simon Papillon‐Cavanagh, Jeremy Schwartzentruber, Hamid Nikbakht, Noha Gerges, Pierre Fiset, Denise Béchet, Damien Faury, Nicolas Jay, Lori Ramkissoon, Aoife Corcoran, David Jones, Dominik Sturm, Pascal D. Johann, Tadanori Tomita, Stewart Goldman, Mahmoud G. Nagib, Anne Bendel, Liliana Goumnerova, Daniel C. Bowers, Jeffrey R Leonard, Joshua B. Rubin, Tord D. Alden, Samuel R. Browd, J. Russell Geyer, Sarah Leary, George I. Jallo, Kenneth J. Cohen, Nalin Gupta, Michael D. Prados, Anne‐Sophie Carret, Benjamin Ellezam, Louis Crevier, Álmos Klekner, László Bognár, Péter Hauser, Miklós Garami, John S. Myseros, Zhifeng Dong, Peter M. Siegel, Hayley Malkin, Azra H. Ligon, Steffen Albrecht, Stefan M. Pfister, Keith L. Ligon, Jacek Majewski, Nada Jabado, Mark W. Kieran
S137905309. 2014472 CitationsOPEN ACCESS
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip
Journal of Clinical Oncology. 2017420 CitationsOPEN ACCESS
How much of the research on NGM Biopharmaceuticals (United States) is open access?
ScholarIQopen access share
83%OPEN ACCESS
Gold
25%
Green
42%
Hybrid
0%
Bronze
17%
Closed
17%